RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC

Adam Christian Vilmar; J Garcia-Foncillas; M Huarriz; E Santoni-Rugiu; J B Sorensen; Adam Christian Vilmar

doi:10.1016/j.lungcan.2011.08.016

RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC

Adam Christian Vilmar, J Garcia-Foncillas, M Huarriz, E Santoni-Rugiu, J B Sorensen, Adam Christian Vilmar

Bachelor- og kandidatuddannelser

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

45 Citationer (Scopus)

Abstract

Customized chemotherapy is increasingly used in the management of patients with advanced non-small cell lung cancer (NSCLC). However, the most reliable methodology to determine biomarker status is neither fully elucidated nor agreed upon. Accordingly, we evaluated the predictive efficiency of qRT-PCR and immunohistochemical analysis (IHC) on excision cross complementation group 1 (ERCC1), breast cancer susceptibility gene 1 (BRCA1), ribonucleotide reductase subunit M1 (RRM1) and class III ß-tubulin (TUBB3).

Originalsprog	Engelsk
Tidsskrift	Lung Cancer
Vol/bind	75
Udgave nummer	3
Sider (fra-til)	306-12
Antal sider	7
ISSN	0169-5002
DOI	https://doi.org/10.1016/j.lungcan.2011.08.016
Status	Udgivet - 2012

Adgang til dokumentet

10.1016/j.lungcan.2011.08.016

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

@article{c4143d1a3e9b4add98df50ab213fe465,

title = "RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC",

abstract = "Customized chemotherapy is increasingly used in the management of patients with advanced non-small cell lung cancer (NSCLC). However, the most reliable methodology to determine biomarker status is neither fully elucidated nor agreed upon. Accordingly, we evaluated the predictive efficiency of qRT-PCR and immunohistochemical analysis (IHC) on excision cross complementation group 1 (ERCC1), breast cancer susceptibility gene 1 (BRCA1), ribonucleotide reductase subunit M1 (RRM1) and class III {\ss}-tubulin (TUBB3).",

author = "Vilmar, {Adam Christian} and J Garcia-Foncillas and M Huarriz and E Santoni-Rugiu and Sorensen, {J B} and Vilmar, {Adam Christian}",

year = "2012",

doi = "10.1016/j.lungcan.2011.08.016",

language = "English",

volume = "75",

pages = "306--12",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC

AU - Vilmar, Adam Christian

AU - Garcia-Foncillas, J

AU - Huarriz, M

AU - Santoni-Rugiu, E

AU - Sorensen, J B

AU - Vilmar, Adam Christian

PY - 2012

Y1 - 2012

N2 - Customized chemotherapy is increasingly used in the management of patients with advanced non-small cell lung cancer (NSCLC). However, the most reliable methodology to determine biomarker status is neither fully elucidated nor agreed upon. Accordingly, we evaluated the predictive efficiency of qRT-PCR and immunohistochemical analysis (IHC) on excision cross complementation group 1 (ERCC1), breast cancer susceptibility gene 1 (BRCA1), ribonucleotide reductase subunit M1 (RRM1) and class III ß-tubulin (TUBB3).

AB - Customized chemotherapy is increasingly used in the management of patients with advanced non-small cell lung cancer (NSCLC). However, the most reliable methodology to determine biomarker status is neither fully elucidated nor agreed upon. Accordingly, we evaluated the predictive efficiency of qRT-PCR and immunohistochemical analysis (IHC) on excision cross complementation group 1 (ERCC1), breast cancer susceptibility gene 1 (BRCA1), ribonucleotide reductase subunit M1 (RRM1) and class III ß-tubulin (TUBB3).

U2 - 10.1016/j.lungcan.2011.08.016

DO - 10.1016/j.lungcan.2011.08.016

M3 - Journal article

C2 - 21996087

SN - 0169-5002

VL - 75

SP - 306

EP - 312

JO - Lung Cancer

JF - Lung Cancer

IS - 3

ER -